

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR EUROPE

WELTGESUNDHEITSORGANISATION
REGIONALBÜRO FÜR EUROPA

WORLD HYPERTENSION LEAGUE



ORGANISATION MONDIALE DE LA SANTÉ
BUREAU RÉGIONAL DE L'EUROPE

ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО

LIGUE MONDIALE CONTRE L'HYPERTENSION


32429

EUR/ICP/NCD 020
2124s
ENGLISH ONLY
UNEDITED

MEETING OF THE PRINCIPAL INVESTIGATORS
OF THE HYPERTENSION MANAGEMENT AUDIT PROJECT OF THE
WHO EUROPEAN HYPERTENSION RESEARCH ACTION PROGRAMME (HYRAP)

Report on a joint meeting of the
World Hypertension League and the
World Health Organization

Tel Aviv
4 December 1988



1989

EUR/HFA target 9
A target 9

This document does not constitute formal publication. It should not be reprinted, abstracted or quoted without the agreement of the World Health Organization Regional Office for Europe. Authors alone are responsible for views expressed in signed articles.

Dieses Dokument erscheint nicht als formelle Veröffentlichung. Es darf nicht mit Genehmigung des Regionalbüros für Europa der Weltgesundheitsorganisation besprochen, in Kurzfassung gebracht oder zitiert werden. Beiträge, die mit Namensunterschrift erscheinen, geben ausschließlich die Meinung des Autors wieder.

This document ne constitue par une publication. Il ne doit faire l'objet d'aucun compte rendu ou résumé ni d'aucune citation sans l'autorisation du Bureau régional de l'Europe de l'Organisation Mondiale de la Santé. Les opinions exprimées dans les articles signés n'engagent que leurs auteurs.

Настоящий документ не является официальной публикацией. Не разрешается репринтировать, абстрагировать или цитировать этот документ без согласия Европейского регионального бюро Всемирной организации здравоохранения. Вся ответственность за взгляды, выраженные в подписанных авторами статьях, несёт сами авторы.

TARGET 9

Combating diseases of the circulatory system

By the year 2000, mortality in the Region from diseases of the circulatory system in people under 65 should be reduced by at least 15%.

Index:

HYPERTENSION
HEALTH SURVEYS
RESEARCH

CONTENTS

	<u>Page</u>
1. Introduction	1
2. Reports from participating centres	1
3. Plans for publication of audit data	2
3.1 A "large publication"	3
3.2 A "summary publication"	3
3.3 "National publications"	3
3.4 Preparation of manuscripts	3
4. Closing remarks	3

1. Introduction

On 4 December 1988, investigators participating in the joint WHO/World Hypertension League (WHL) meeting of the Principal Investigators of the Hypertension Management Audit Project of the WHO European Hypertension Research Action Programme (HYRAP) met in Tel Aviv, Israel. This meeting took place in conjunction with the Third International Symposium on Hypertension in the Community which was held on 5-8 December. Two other related meetings concerning hypertension had also taken place at the same locale immediately before: a meeting of the Council of WHL on 3 December, and the International Patient Education Workshop on 1-2 December.

At the opening session participants were welcomed by Dr A. Shatchkute, Regional Officer for Chronic Diseases, WHO Regional Office for Europe, Mrs Pnina Herzog, Director, International Relations, Ministry of Health of Israel and by Dr T. Strasser, Secretary General of WHL. Dr L. Wilhelmsen was elected as chairman of the meeting, Dr T. Rosenthal as vice-chairman and Dr E. Brenner as rapporteur. A list of participants is attached as Annex 1 and the Programme is given in Annex 2.

2. Reports from participating centres

The rest of the morning session and the first part of the afternoon were devoted to 12 reports presented by investigators from the participating centres from nine countries. A list of these reports is presented in Annex 2 under the Programme.

Reports covered the five areas of the Hypertension Management Audit Protocol: (1) community surveys; (2) patient surveys; (3) consumer surveys; (4) physician inquiries, and (5) drug utilization studies. Some centres had completed work in all of these areas, others only in one or more of them. A matrix summarizing which areas have been covered by work from which investigators is presented in Annex 3.

Numerous problems and issues of general interest were raised during the discussion period which followed each of the individual presentations including points concerning:

- the need to standardize practice and record keeping systems (e.g. hypertension registries) for busy practitioners;
- the problem of digit preference (e.g. for digits ending with 0 or 5) and whether this might be solved in the future by BP recording devices which provide a printout of the BP measurement;
- the numerous sources of methodologic inconsistency which can lead, from a clinical point of view, to problems with non-comparability of data. These inconsistencies relate to such factors as: failure to use BP cuffs of different sizes for different size arms (and inconsistent use of tables for corrections), variation in patient position at time of BP measurement, variations in the speed with which the column of mercury is allowed to descend while listening for Korotkoff (K) sounds, use of K4 rather than the K5 sound for determining diastolic pressure, wide differences in how often sphygmomanometers are standardized;

- the value, when recruiting practitioners for the physician inquiry survey of having a letter signed not only by the principal investigators, but also by the local medical association and the local health authorities;
- problems related to patient selection bias (e.g. if only employed individuals are surveyed);
- the value of standardizing BP results by age when BP data for different populations are being compared;
- the interest in comparing data for drug utilization which come from several sources such as patient interviews, physician interviews, drug store sales, prescription review data and so forth. It was pointed out that these and other sources of information are complementary and that, when they give similar data, each method may serve to validate the other. On the other hand, discrepancies noted between sources of information may, at least in part, be explained by the fact that some refer to patients, but others to doses, prescriptions or sales. All of these are, in any case, still only indirect indicators regarding actual patient usage;
- the importance of not phrasing questions in such a "leading way" that the subject of the interview (patient or practitioner) may be led to answer the question one way rather than another;
- questions regarding how often various surveys should be done. This question led to a good discussion which emphasized that the community audit protocols are unlike most clinical trial protocols, which are of the type usually carried out only once. On the contrary, it was pointed out that it is likely to be of value to repeat various parts of the hypertension audits, e.g. concerning physician attitudes and practices or drug utilization so that the situation in different regions can be monitored over time. Thus surveys can be used not only to compare countries with each other, as well as different areas within countries, but as well to allow an area to be compared with itself over a period of time.
- the possibility that data concerning drug utilization might be available from a number of countries in the European region (Belgium, Finland, Norway, Sweden) which have not so far been involved with the audit, but which do already have some institutional methodology for collecting data on pharmacologic products. With such data from a number of countries, it might then be possible to "calibrate" or "correct" data from those countries where it is not always possible to discern the extent to which certain products are used to treat hypertension since they (e.g. beta-blockers) are also used to treat other conditions such as angina pectoris or cardiac arrhythmias.

3. Plans for publication of audit data

It was proposed that the investigations completed to date may be published in several ways so as to reach a wide and varied audience:

3.1 A "large publication"

This would include details concerning all the investigations carried out to date. One alternative discussed was to have this prepared as a WHO publication which would offer clear advantages for reaching ministries of health in many countries. Another alternative would be that of a special supplement to a medical journal, though one obstacle to this option is the level of funding generally required.

3.2 A "summary publication"

The proposal here was for a short summary just a few pages in length, to be submitted to one of the principal journals which reaches the "hypertension community". It was a definite decision that this type of publication should be prepared whatever the outcome of 3.1.

3.3 "National publications"

It was discussed that the eventual publishing either of a complete review of all work done to date and/or of a short summary in an international journal, should not preclude in any way individual investigators from publishing their results in their native language journals. In fact, the group agreed on the benefit of aiming for a range of different types of publications which can thus reach a wide and varied audience.

3.4 Preparation of manuscripts

It was agreed that publication-ready manuscripts should be submitted as soon as possible with copies to go to both Professor Wilhelmsen and Dr Strasser who will take on the responsibility for editing and coordinating publications (except the "national publications"). It is understood that they will need to retain some "editorial leeway" in order to achieve necessary unity of style and form.

4. Closing remarks

In his closing remarks, Dr A. Amery, President of the WHL, expressed satisfaction at the progress made to date. Along with Professor Wilhelmsen and Dr Strasser, he suggested that discussions regarding refinements and revisions in the audit protocols could best be done in small informal group meetings. Finally, he expressed gratitude to Boehringer, Ingelheim, for their generous sponsorship, to the Israeli Hypertension Society for their work as hosts of the meeting and to WHO for its collaboration which should continue in the future.

LIST OF PARTICIPANTS

Dr A. Amery
Sint-Rafael, Gasthuisberg
Herestraat 49
B-3000 Leuven

Dr E. Brenner
Département de médecine communautaire
Faculté de médecine
Hôpital cantonal
Bd. de la Cluse
CH-1211 Geneva

Dr V. Canonico
Via Vincenzo Padula 2
I-80123 Naples

Dr C. Carp
Head, Cardiology Clinic Medical
Institute
Fundeni Hospital
Fundeni Street 253
R-Bucharest

Professor M. Carrageta
Hospital de Santa Maria
Av. Egas Moniz
P-1699 Lisboa

Dr J. Duba
National Institute of Cardiology
IX, Haman Kato ut 29
H-1450 Budapest

Dr A. Füller
German Institute for
High Blood Pressure Research
Bahnhöferstrasse 1
D-6900 Heidelberg 1

Professor P. Jezersek
Univeritetni Klinicni Center
Vodnikova 62
YU-61000 Ljubljana

Dr Luigi La Vecchia
Divisione di Cardiologia
Ospedale Civile
Viale Rodolfi 1
I-86100 Vicenza

Dr K. M'Buyamba-Kabangu
Département de Médecine Interne
Clinique Universitaire
Kinshasa XI
République du Zaïre

Dr E. Mota
R. Gonçalo Velho Cabral 48-3°E
P-1400 Lisbon

Dr P. Nilsson
Health Science Centre
S-24010 Dalby

Dr S. Padamavati
Al 116 Safdarjung Enclave
New Delhi 110029
India

Dr H. Pardell-Alenta
Spanish League Against Arterial Hypertension
Apartado de Correos 46.234
E-28080 Madrid

Dr L. Ramsay
University Department of Therapeutics
Royal Hallamshire Hospital
Glossop Road
GB-Sheffield S10 2JF

Professor T. Rosenthal
The Chaim Sheba Medical Centre
52621 Tel Hashomer
Israel

Professor M. Stanulovic
Department of Pharmacology
Faculty of Medicine
YU-21000 Novi Sad

Dr H. Steinberg
Ruhr Universität Bochum
Medizinische Fakultät
Abteilung für Sozialmedizin und
Epidemiologie
D-4630 Bochum 1

Dr T. Strasser
World Hypertension League
Av. du Bouchet 20
CH-1209 Geneva

Dr M. Torner i Soler
Generalitat de Catalunya
Department de Sanitat I
Seguretat Social
Avgda. de Roma 157
E-Barcelona 11

Dr E. Török
Hungarian Institute of Cardiology
P.O.B. 88
Haman Kato ut 29
H-1450 Budapest

Dr H. Ueshima
National Cardiovascular Center
5-7-1 Fufishiro-Dai
Suita
Osaka 565
Japan

Dr R. Viskoper
Head, Department Medicine B and
Hypertension Unit
Barzilai Medical Center
Ashkelon 78306
Israel

Professor L. Wilhelmsen
Chief, Department of Medicine
Ostra Hospital
S-416 85 Gothenburg

Dr S. Zamboni
Clinica Medica 1
Via Giustiniani 2
I-35126 Padova

Dr G. Zeltner
Head, Department of Internal Medicine
Miskolc Megyei Korhaz
Szentpékri Kapu 76
H-3525 Miskolc

OBSERVERS

Dr R. Badenhoop
German Institute for
High Blood Pressure Research
Berliner Str. 46
D-6900 Heidelberg

Dr M. Bajic
Dept. of Physiology
Medical Faculty
University of Novi Sad
YU-21000 Novi Sad

Dr J. Ben Ari
Hacarmel Hospital
7 Michel Street
Haifa
Israel

Dr J. Bernheim
Department of Nephrology
Meir Hospital
Kfar Saba
Israel

Professor D. Brunner
Department of Internal Medicine A
E. Wolfson Medical Centre
Tel-Aviv University
P.O. Box 5
58100 Tel Giborim, Holon
Israel

Dr M. Fostick
Computer Unit
Meir Hospital
Kfar Saba
Israel

Dr Gladigau
Boehringer Ingelheim
Zentrale GmbH
D-6507 Ingelheim am Rhein

Dr E. Kirsch
Ichilov Hospital
6 Weizman Strasse
Tel Aviv
Israel

Dr E. Paran
Hypertension Clinic
Soroka Medical Centre
Ber Sheba
Israel

Professor S. Rogel
Machon Lev Hayerushalmi
Hadasseh Medical School
Department of Cardiology
Jerusalem 91010
Israel

Dr K. Schuster
Boehringer Ingelheim GmbH
Zentrale
D-6507 Ingelheim am Rhein

Dr Y.M. Traub
Hypertension Unit Centre
Beilinson Medical Centre
Petah Tiqvah
Israel

Mr J.P. Willaert
Director, Belgian League of Cardiology
Hôtel des Sociétés Scientifiques
Rue des Champs-Elysées 43
B-1050 Bruxelles

Dr Y. Yodfat
Hebrew University Hadassal Medical School
Department of Family Medicine
Jerusalem 91010
Israel

Dr Liu Zhang
Division of Hypertension
Cardiovascular Disease Institute
Chinese Academy of Medical Science
Beijing (Peoples Republic of China)

WORLD HEALTH ORGANIZATION

Regional Office for Europe

Dr A. Shatchkute
Regional Officer for Chronic Diseases

Ms P. Griffiths
Secretary, Chronic Diseases Unit

PROGRAMME/LIST OF REPORTS GIVEN

1. Opening of the meeting
Address by Dr Aushra Shatchkute, WHO
Address by Dr Pnina Herzog, Ministry of Health, Jerusalem
Address by Dr T. Strasser, WHL
2. Election of Chairman, Co-Chairman and Rapporteur
3. Introduction by Dr L. Wilhelmsen
4. Reports from participating centres
 - 4.1 E. Brenner: Cluster sampling to assess coverage with blood pressure measurements in a Swiss urban population. Report of a field survey using public health.
 - 4.2 E. Török: Hungarian Audit Project: Community survey and screening. Reexamination I and reexamination II.
 - 4.3 R.J. Viskoper: The Ashkelon hypertension detection and follow-up program.
 - 4.4 M. Carrageta: Report from Madeira, Portugal.
 - 4.5 C. Carp: Detection, evaluation and treatment of high blood pressure in workers.
 - 4.6 L. La Vecchia: The audit project in the community of Vicenza: preliminary results.
 - 4.7 M. Stanulovic: Comparison of three methods for the measurement of compliance with antihypertensive drug treatment.
 - 4.8 P. Jezersek: Hypertension control and management in Slovenia, Yugoslavia.
 - 4.9 A. Füller: Treatment of mild hypertension in primary health care - Results of a physician's inquiry in Stuttgart 1986.
 - 4.10 H. Steinberg et al: Knowledge and attitude of physicians in four large cities in the Federal Republic of Germany concerning hypertension control and management.
 - 4.11 M. Torner i Soler: Results from the physician inquiry in Catalonia, Spain.
 - 4.12 M. Stanulovic: Assessment of the adequacy of antihypertensive drug prescription in a Yugoslav community.
5. Guidelines for data analysis and presentation
6. Plans for further action
7. Publication
8. Conclusions
9. Closure

Status of Hypertension Management Audit Projects
from investigators collaborating with WHO/WHL *

<u>Principal Investigator</u>	<u>Community Survey</u>	<u>Patient Survey</u>	<u>Consumer Survey</u>	<u>Physician Inquiry</u>	<u>Drug Utilization</u>
Brenner	F	---	---	---	---
Török	F	f	f	f	f
Viskoper	F	F		F	
Carrageta	f	S	S	f	I
Carp	F	F	F	F	---
La Vecchia	F	F	F	F	I ?
Stanulovic	S	S	S	S	P/S
Jezersek	F	F	F	F	F
Füller	P	---	---	P	f
Steinberg	P	I	I	F	F
Torner i Soler	F	S	---	F	I-S
IHS/Rosenthal	S	S	S	S	S
Padmavati	S	S	S	S	S
Spanish League	---	---	---	---	---
Dal Palu	F	---	---	S	f
Canonico	F	S	f	F	---
Klumbiene	f	I	I	f	I

* F = Finished/f = almost finished/S = Started/I = Intended
P = Publication ready